
Fausto Bogazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/466835/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Editorial commentary: The striking prevalence of amiodarone induced hypothyroidism: an endocrinologist's perspective. Trends in Cardiovascular Medicine, 2023, 33, 263-264.	4.9	1
2	Salvage total thyroidectomy for amiodarone-induced thyrotoxicosis in a SARS-CoV-2 positive patient: results of the viral genome research on the pathology sample of this destructive thyroiditis. Endocrine, 2022, 76, 495-498.	2.3	2
3	Early surgery: a favorable prognosticator in amiodarone-induced thyrotoxicosis—a single-center experience with 53 cases. Updates in Surgery, 2022, 74, 1413-1418.	2.0	3
4	PCB153 reduces apoptosis in primary cultures of murine pituitary cells through the activation of NF-κB mediated by PI3K/Akt. Molecular and Cellular Endocrinology, 2021, 520, 111090.	3.2	8
5	Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests. Thyroid, 2021, 31, 1463-1471.	4.5	4
6	Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 242-251.	3.6	36
7	Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3427-e3436.	3.6	13
8	Heart Drugs and Influences on TH Metabolism. , 2020, , 311-325.		4
9	Response to the Letter to the Editor: "Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3036-e3037.	3.6	2
10	Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients. Endocrinology, Diabetes and Metabolism, 2019, 2, e00033.	2.4	5
11	Thyrotoxicosis Factitia. , 2018, , 693-694.		0
12	2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. European Thyroid Journal, 2018, 7, 55-66.	2.4	165
13	Amiodarone and Thyroid. , 2018, , 782-786.		1
14	Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. European Journal of Endocrinology, 2017, 177, 127-135.	3.7	26
15	Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS ONE, 2017, 12, e0186485.	2.5	31
16	Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. European Journal of Endocrinology, 2016, 175, 443-453.	3.7	29
17	The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation, 2016, 39, 585-591.	3.3	24
18	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Journal of Neuro-Oncology, 2016, 126, 519-525.	2.9	105

#	Article	IF	CITATIONS
19	Divergent Effects of Dioxin- or Non-Dioxin-Like Polychlorinated Biphenyls on the Apoptosis of Primary Cell Culture from the Mouse Pituitary Gland. PLoS ONE, 2016, 11, e0146729.	2.5	18
20	Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. Journal of Endocrinological Investigation, 2015, 38, 1099-1109.	3.3	12
21	Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. Journal of Endocrinological Investigation, 2015, 38, 605-613.	3.3	41
22	ACROSTUDY: the Italian experience. Endocrine, 2015, 48, 334-341.	2.3	38
23	A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (Aip) gene in an Italian family with gigantism. Journal of Endocrinological Investigation, 2014, 37, 949-955.	3.3	9
24	The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clinical Endocrinology, 2014, 81, 573-581.	2.4	21
25	Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. European Journal of Endocrinology, 2014, 170, 247-254.	3.7	15
26	Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. Journal of Endocrinological Investigation, 2014, 37, 1017-1030.	3.3	45
27	Lower Prolactin Levels During Cabergoline Treatment are Associated to Tumor Shrinkage in Prolactin Secreting Pituitary Adenoma. Hormone and Metabolic Research, 2014, 46, 939-942.	1.5	12
28	The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology, 2014, 171, 363-368.	3.7	43
29	Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. Endocrine Practice, 2013, 19, 1043-1049.	2.1	16
30	Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol. European Journal of Endocrinology, 2013, 168, 315-321.	3.7	61
31	Growth Hormone Is Necessary for the p53-Mediated, Obesity-Induced Insulin Resistance in Male C57BL/6J × CBA Mice. Endocrinology, 2013, 154, 4226-4236.	2.8	19
32	Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. European Journal of Endocrinology, 2013, 169, 367-376.	3.7	35
33	Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2013, 36, 174-9.	3.3	11
34	Serum factors associated with precancerous colonic lesions in acromegaly. Journal of Endocrinological Investigation, 2013, 36, 545-9.	3.3	5
35	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E165-E172.	3.6	41
36	Total Thyroidectomy in Patients with Amiodarone-Induced Thyrotoxicosis and Severe Left Ventricular Systolic Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3515-3521.	3.6	58

#	Article	IF	CITATIONS
37	The mechanisms of nadroparinâ€mediated inhibition of proliferation of two human lung cancer cell lines. Cell Proliferation, 2012, 45, 545-556.	5.3	20
38	Serum Insulin-Like Growth Factor-1 Concentrations Are Reduced in Severely Obese Women and Raise After Weight Loss Induced by Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2012, 22, 1276-1280.	2.1	38
39	Rathke's cleft cysts in children: clinical, diagnostic, and surgical features. Child's Nervous System, 2012, 28, 297-303.	1.1	9
40	Amiodarone and the thyroid: a 2012 update. Journal of Endocrinological Investigation, 2012, 35, 340-8.	3.3	66
41	Effectofrosiglitazoneonserum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results froma pilot phase 2 study. Journal of Endocrinological Investigation, 2011, 34, e43-e51.	3.3	13
42	Continuation of Amiodarone Delays Restoration of Euthyroidism in Patients with Type 2 Amiodarone-Induced Thyrotoxicosis Treated with Prednisone: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3374-3380.	3.6	49
43	Impact of different cut-off limits of peak GH after GHRH-arginine stimulatory test, single IGF1 measurement, or their combination in identifying adult patients with GH deficiency. European Journal of Endocrinology, 2011, 164, 685-693.	3.7	13
44	Cardiac extrinsic apoptotic pathway is silent in young but activated in elder mice overexpressing bovine CH: interplay with the intrinsic pathway. Journal of Endocrinology, 2011, 210, 231-238.	2.6	5
45	Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. European Journal of Endocrinology, 2011, 164, 341-347.	3.7	44
46	Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome. Hormone and Metabolic Research, 2011, 43, 126-129.	1.5	0
47	Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects. Journal of Endocrinological Investigation, 2011, 34, e200-3.	3.3	30
48	Pituitary autoimmunity is associated with hypopituitarism in patients with primary empty sella. Journal of Endocrinological Investigation, 2011, 34, e240-4.	3.3	19
49	Diagnosis and treatment of autoimmune hypophysitis: a short review. Journal of Endocrinological Investigation, 2011, 34, e245-52.	3.3	24
50	Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodaroneâ€induced thyrotoxicosis: a cautionary note. Clinical Endocrinology, 2010, 72, 133-134.	2.4	23
51	Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2529-2535.	3.6	166
52	Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. European Journal of Endocrinology, 2010, 163, 783-791.	3.7	110
53	Tumor Infiltrating Lymphocytes But Not Serum Pituitary Antibodies Are Associated with Poor Clinical Outcome after Surgery in Patients with Pituitary Adenoma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 289-296.	3.6	42
54	Impact of Lithium on Efficacy of Radioactive lodine Therapy for Graves' Disease: A Cohort Study on Cure Rate, Time to Cure, and Frequency of Increased Serum Thyroxine After Antithyroid Drug Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 201-208.	3.6	75

#	Article	IF	CITATIONS
55	Glucocorticoids Are Preferable to Thionamides as First-Line Treatment for Amiodarone-Induced Thyrotoxicosis due to Destructive Thyroiditis: A Matched Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3757-3762.	3.6	51
56	High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European Journal of Endocrinology, 2009, 161, 331-338.	3.7	109
57	Regulation of cardiac fatty acids metabolism in transgenic mice overexpressing bovine GH. Journal of Endocrinology, 2009, 201, 419-427.	2.6	11
58	Reduced colonic apoptosis in mice overexpressing bovine growth hormone occurs through changes in several kinase pathways. Growth Hormone and IGF Research, 2009, 19, 432-441.	1.1	5
59	Changes in the expression of suppressor of cytokine signalling (SOCS) 2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps. Clinical Endocrinology, 2009, 70, 898-906.	2.4	9
60	2078 High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in-vivo study using magnetic resonance imaging and integrated backscatter analysis. Journal of Cardiovascular Magnetic Resonance, 2008, 10, .	3.3	1
61	Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice, 2008, 62, 1864-1869.	1.7	83
62	High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clinical Endocrinology, 2008, 68, 361-368.	2.4	54
63	Primary hyperparathyroidism is associated with marked impairment of GH response to acylated ghrelin. Clinical Endocrinology, 2008, 69, 197-201.	2.4	6
64	Diagnosis and management of amiodaroneâ€induced thyrotoxicosis: similarities and differences between North American and European thyroidologists*. Clinical Endocrinology, 2008, 69, 812-818.	2.4	75
65	Serum pituitary antibodies in normal pregnancy and in patients with postpartum thyroiditis: a nested case–control study. European Journal of Endocrinology, 2008, 159, 805-809.	3.7	13
66	Identification, treatment and management of cardiovascular risks in patients with acromegaly. Expert Review of Endocrinology and Metabolism, 2008, 3, 603-614.	2.4	1
67	Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?. European Journal of Endocrinology, 2008, 159, 359-361.	3.7	25
68	Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 70-71.	2.8	36
69	Transgenic Mice Overexpressing Growth Hormone (GH) Have Reduced or Increased Cardiac Apoptosis through Activation of Multiple GH-Dependent or -Independent Cell Death Pathways. Endocrinology, 2008, 149, 5758-5769.	2.8	22
70	Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH. Journal of Endocrinology, 2007, 194, 521-527.	2.6	7
71	Glucocorticoid Response in Amiodarone-Induced Thyrotoxicosis Resulting from Destructive Thyroiditis Is Predicted by Thyroid Volume and Serum Free Thyroid Hormone Concentrations. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 556-562.	3.6	70
72	Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A Five-Year Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4271-4277.	3.6	91

#	Article	IF	CITATIONS
73	Prevalence and Functional Significance of Antipituitary Antibodies in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2176-2181.	3.6	74
74	Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clinical Endocrinology, 2007, 67, 070611013542001-???.	2.4	47
75	Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. Langenbeck's Archives of Surgery, 2007, 392, 709-713.	1.9	17
76	Abnormal expression of PPAR gamma isoforms in the subcutaneous adipose tissue of patients with Cushing's disease. Clinical Endocrinology, 2006, 66, 060904075417002-???.	2.4	2
77	Bone and joint alterations in acromegaly. Journal of Orthopaedics and Traumatology, 2006, 7, 169-175.	2.3	3
78	Identification of Acromegalic Patients at Risk of Developing Colonic Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1351-1356.	3.6	48
79	The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment. European Journal of Endocrinology, 2006, 155, 41-45.	3.7	2
80	Thyroid Color Flow Doppler Sonography: An Adjunctive Tool for Differentiating Patients with Inappropriate Thyrotropin (TSH) Secretion Due to TSH-Secreting Pituitary Adenoma or Resistance to Thyroid Hormone. Thyroid, 2006, 16, 989-995.	4.5	17
81	Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study. Clinical Endocrinology, 2005, 62, 590-596.	2.4	36
82	Apoptosis is reduced in the colonic mucosa of patients with acromegaly. Clinical Endocrinology, 2005, 63, 683-688.	2.4	22
83	Treatment with Thionamides before Radioiodine Therapy for Hyperthyroidism: Yes or No?. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1256-1256.	3.6	6
84	An update on the pharmacological management of hyperthyroidism due to Graves' disease. Expert Opinion on Pharmacotherapy, 2005, 6, 851-861.	1.8	12
85	Large vestibular aqueduct syndrome: audiological, radiological, clinical, and genetic features. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2005, 26, 363-371.	1.3	96
86	Growth Hormone Inhibits Apoptosis in Human Colonic Cancer Cell Lines: Antagonistic Effects of Peroxisome Proliferator Activated Receptor-Î ³ Ligands. Endocrinology, 2004, 145, 3353-3362.	2.8	30
87	PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. European Journal of Endocrinology, 2004, 150, 863-875.	3.7	37
88	Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clinical Endocrinology, 2004, 61, 494-502.	2.4	78
89	La gestione del paziente nella tireotossicosi e nell'ipotiroidismo indotti da amiodarone. L Endocrinologo, 2004, 5, 31-38.	0.0	0
90	Improvement of Growth Hormone Deficiency in Patients with Primary Hyperparathyroidism after Parathyroidectomy: Results of a Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1213-1216.	3.6	10

#	Article	IF	CITATIONS
91	Thyrotoxicosis Factitia. , 2004, , 551-553.		0
92	Impaired GH secretion to provocative stimuli in two families with hypocalciuric hypercalcaemia. Clinical Endocrinology, 2003, 59, 604-606.	2.4	6
93	Colonic polyps of acromegalic patients are not associated with mutations of the peroxisome proliferator activated receptor 13 gene. Journal of Endocrinological Investigation, 2003, 26, 1054-1058.	3.3	4
94	The Prevalence of Elevated Serum C-Reactive Protein Levels in Inflammatory and Noninflammatory Thyroid Disease. Thyroid, 2003, 13, 643-648.	4.5	84
95	Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1999-2002.	3.6	77
96	Changes in the Expression of the Peroxisome Proliferator-Activated Receptor Î ³ Gene in the Colonic Polyps and Colonic Mucosa of Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3938-3942.	3.6	19
97	Submandibular salivary gland volume is increased in patients with acromegaly. Clinical Endocrinology, 2002, 57, 97-100.	2.4	11
98	Thyroid vascularity is increased in patients with active acromegaly. Clinical Endocrinology, 2002, 57, 65-70.	2.4	16
99	Peroxisome Proliferator Activated Receptor Î ³ Expression Is Reduced in the Colonic Mucosa of Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2403-2406.	3.6	30
100	Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4490-4495.	3.6	69
101	Adjuvant Effect of Lithium on Radioiodine Treatment of Hyperthyroidism. Thyroid, 2002, 12, 1153-1154.	4.5	15
102	Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery, 2002, 132, 1114-1118.	1.9	59
103	Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge*. Clinical Endocrinology, 2002, 56, 23-24.	2.4	49
104	Peroxisome Proliferator Activated Receptor Expression Is Reduced in the Colonic Mucosa of Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2403-2403.	3.6	23
105	The Various Effects of Amiodarone on Thyroid Function. Thyroid, 2001, 11, 511-519.	4.5	135
106	The Effects of Amiodarone on the Thyroid*. Endocrine Reviews, 2001, 22, 240-254.	20.1	389
107	The Effects of Amiodarone on the Thyroid. , 2001, 22, 240-254.		163
108	A novel mutation in the pendrin gene associated with Pendred's syndrome. Clinical Endocrinology, 2000, 52, 279-285.	2.4	26

#	Article	lF	CITATIONS
109	Amiodarone Induces Cytochrome <i>c</i> Release and Apoptosis through an Iodine-Independent Mechanism ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4323-4330.	3.6	49
110	Pendrin does not increase sulfate uptake in mammalian COS-7 cells. Journal of Endocrinological Investigation, 2000, 23, 170-172.	3.3	12
111	Color Flow Doppler Sonography of the Thyroid. , 2000, , 215-238.		3
112	Iodide Excess Induces Apoptosis in Thyroid Cells through a p53-Independent Mechanism Involving Oxidative Stress. Endocrinology, 2000, 141, 598-605.	2.8	45
113	Amiodarone Induces Cytochrome c Release and Apoptosis through an Iodine-Independent Mechanism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4323-4330.	3.6	43
114	Comparison of Radioiodine with Radioiodine plus Lithium in the Treatment of Graves' Hyperthyroidism1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 499-503.	3.6	73
115	Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. European Journal of Endocrinology, 1999, 140, 452-456.	3.7	113
116	Comparison of Radioiodine with Radioiodine plus Lithium in the Treatment of Graves' Hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 499-503.	3.6	58
117	Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy. New England Journal of Medicine, 1998, 338, 73-78.	27.0	644
118	Role of conventional ultrasonography and color flow-doppler sonography in predicting malignancy in 'cold' thyroid nodules. European Journal of Endocrinology, 1998, 138, 41-46.	3.7	299
119	Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology, 1998, 138, 603-614.	3.7	84
120	Color Flow Doppler Sonography Rapidly Differentiates Type I and Type II Amiodarone-Induced Thyrotoxicosis. Thyroid, 1997, 7, 541-545.	4.5	173
121	l-thyroxine directly affects expression of thyroid hormone-sensitive genes: regulatory effect of RXRβ. Molecular and Cellular Endocrinology, 1997, 134, 23-31.	3.2	25
122	Adverse Effects of Thyroid Hormone Preparations and Antithyroid Drugs. Drug Safety, 1996, 15, 53-63.	3.2	88
123	Surgical treatment of graves' disease: Subtotal or total thyroidectomy?. Surgery, 1996, 120, 1020-1025.	1.9	151
124	Measurement of Serum Free Thyroid Hormone Concentrations: An Essential Tool for the Diagnosis of Thyroid Dysfunction. Hormone Research, 1996, 45, 142-147.	1.8	46
125	Graves' Disease Occurring after Subacute Thyroiditis: Report of a Case and Review of the Literature. Thyroid, 1996, 6, 345-348.	4.5	59
126	Radioiodine and thyroid-associated ophthalmopathy. Orbit, 1996, 15, 197-203.	0.8	5

#	Article	IF	CITATIONS
127	Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2930-2933.	3.6	160
128	Cigarette smoking and the thyroid. European Journal of Endocrinology, 1995, 133, 507-512.	3.7	108
129	Non-autoimmune hyperthyroidism associated with isolated bilateral ocular lymphoma mimicking Graves' disease with ophthalmopathy: A cause of misdiagnosis. Journal of Endocrinological Investigation, 1995, 18, 817-819.	3.3	9
130	Site-Specific Anti-C-ERB A Antibodies Recognizing Native Thyroid Hormone Receptors: Their use to Detect the Expression and Localization of I± and I² C-ERB A Proteins in Rat Liver. Journal of Receptors and Signal Transduction, 1992, 12, 201-215.	1.2	12
131	Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. Journal of Endocrinological Investigation, 1991, 14, 853-860.	3.3	149
132	The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells. Journal of Endocrinological Investigation, 1990, 13, 917-922.	3.3	8
133	Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Research, 1990, 34, 13-17.	3.3	52
134	Use of Corticosteroids to Prevent Progression of Graves' Ophthalmopathy after Radioiodine Therapy for Hyperthyroidism. New England Journal of Medicine, 1989, 321, 1349-1352.	27.0	296
135	More on smoking habits and Graves' ophthalmopathy. Journal of Endocrinological Investigation, 1989, 12, 733-737.	3.3	187